Homology modeling of the dopamine D2 receptor and its testing by docking of agonists and tricyclic antagonists.
暂无分享,去创建一个
Mark Froimowitz | Boguslaw Stec | B. Stec | M. Froimowitz | M. Teeter | C. Durand | Martha M. Teeter | Curtiss J. DuRand | C. J. Durand
[1] C. Strader,et al. Identification and sequence of a binding site peptide of the beta 2-adrenergic receptor. , 1988, Biochemistry.
[2] B. Roth,et al. A single point mutation (Phe340-->Leu340) of a conserved phenylalanine abolishes 4-[125I]iodo-(2,5-dimethoxy)phenylisopropylamine and [3H]mesulergine but not [3H]ketanserin binding to 5-hydroxytryptamine2 receptors. , 1993, Molecular pharmacology.
[3] K. Neve,et al. Regulation of dopamine D2 receptors by sodium and pH. , 1991, Molecular pharmacology.
[4] J. Thornton,et al. Influence of proline residues on protein conformation. , 1991, Journal of molecular biology.
[5] H. Khorana,et al. Mapping of the amino acids in membrane-embedded helices that interact with the retinal chromophore in bovine rhodopsin. , 1991, The Journal of biological chemistry.
[6] J Hoflack,et al. Three-dimensional models of neurotransmitter G-binding protein-coupled receptors. , 1991, Molecular pharmacology.
[7] D. Grandy,et al. Cloning of the cDNA and gene for a human D2 dopamine receptor. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[8] J. Venter,et al. Site-directed mutagenesis of m1 muscarinic acetylcholine receptors: conserved aspartic acids play important roles in receptor function. , 1989, Molecular pharmacology.
[9] Brian K. Kobilka,et al. Cloning of the gene and cDNA for mammalian β-adrenergic receptor and homology with rhodopsin , 1986, Nature.
[10] S. Vishveshwara,et al. Characterization of proline‐containing α‐helix (helix F model of bacteriorhodopsin) by molecular dynamics studies , 1993, Proteins.
[11] J. Wess. Molecular basis of muscarinic acetylcholine receptor function. , 1993, Trends in pharmacological sciences.
[12] E. Atkinson,et al. Emetic activity of N-substituted norapomorphines. , 1975, Journal of medicinal chemistry.
[13] P. Seeman. Dopamine receptor sequences. Therapeutic levels of neuroleptics occupy D2 receptors, clozapine occupies D4. , 1992, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.
[14] J Hoflack,et al. Re-evaluation of bacteriorhodopsin as a model for G protein-coupled receptors. , 1994, Trends in pharmacological sciences.
[15] J. Nathans,et al. Isolation and nucleotide sequence of the gene encoding human rhodopsin. , 1984, Proceedings of the National Academy of Sciences of the United States of America.
[16] Ovchinnikov YuA. Rhodopsin and bacteriorhodopsin: structure-function relationships. , 1982, FEBS letters.
[17] H Weinstein,et al. Signal transduction by a 5-HT2 receptor: a mechanistic hypothesis from molecular dynamics simulations of the three-dimensional model of the receptor complexed to ligands. , 1993, Journal of medicinal chemistry.
[18] V. Cody,et al. Biologically active conformers of phenothiazines and thioxanthenes. Further evidence for a ligand model of dopamine D2 receptor antagonists. , 1993, Journal of medicinal chemistry.
[19] T. Gallaher,et al. Site-directed mutagenesis of the serotonin 5-hydroxytrypamine2 receptor: identification of amino acids necessary for ligand binding and receptor activation. , 1993, Molecular pharmacology.
[20] M. Whitlow,et al. An empirical examination of potential energy minimization using the well-determined structure of the protein crambin , 1986 .
[21] C. Strader,et al. Identification of residues required for ligand binding to the beta-adrenergic receptor. , 1987, Proceedings of the National Academy of Sciences of the United States of America.
[22] J Hoflack,et al. Modeling of G-protein-coupled receptors: application to dopamine, adrenaline, serotonin, acetylcholine, and mammalian opsin receptors. , 1992, Journal of medicinal chemistry.
[23] P. Seeman,et al. Dopamine receptors and the dopamine hypothesis of schizophrenia , 1987, Synapse.
[24] J. Sack,et al. CHAIN — A crystallographic modeling program , 1988 .
[25] R. Williamson,et al. Evidence for the Importance of a Carboxyl Group in the Binding of Ligands to the D2 Dopamine Receptor , 1990, Journal of neurochemistry.
[26] M. Whitlow,et al. Energy minimization for tertiary structure prediction of homologous proteins: alpha 1-purothionin and viscotoxin A3 models from crambin. , 1985, Journal of biomolecular structure & dynamics.
[27] P. Seeman,et al. Dopamine D1 receptor mutagenesis: role of amino acids in agonist and antagonist binding. , 1993, Biochemical and biophysical research communications.
[28] R. Baldessarini,et al. Synthesis and structural requirements of N-substituted norapomorphines for affinity and activity at dopamine D-1, D-2, and agonist receptor sites in rat brain. , 1990, Journal of medicinal chemistry.
[29] R. Dixon,et al. cDNA for the human beta 2-adrenergic receptor: a protein with multiple membrane-spanning domains and encoded by a gene whose chromosomal location is shared with that of the receptor for platelet-derived growth factor. , 1987, Proceedings of the National Academy of Sciences of the United States of America.
[30] R. Summers,et al. Adrenoceptors and Their Second Messenger Systems , 1993, Journal of neurochemistry.
[31] K. Bogeso,et al. Conformational analysis and structural comparisons of (1R,3S)-(+)- and (1S,3R)-(-)-tefludazine, (S)-(+)- and (R)-(-)-octoclothepin, and (+)-dexclamol in relation to dopamine receptor antagonism and amine-uptake inhibition. , 1988, Journal of medicinal chemistry.
[32] N. Pollock,et al. Serine mutations in transmembrane V of the dopamine D1 receptor affect ligand interactions and receptor activation. , 1992, The Journal of biological chemistry.
[33] E. Eliopoulos,et al. Three-dimensional modelling of G protein-linked receptors. , 1990, Trends in pharmacological sciences.
[34] C. Branden,et al. Introduction to protein structure , 1991 .
[35] R. Deth,et al. Precoupling of Gi/G(o)-linked receptors and its allosteric regulation by monovalent cations. , 1993, Life sciences.
[36] B. Kobilka,et al. Identification of a single amino acid residue responsible for the binding of a class of beta-adrenergic receptor antagonists to 5-hydroxytryptamine1A receptors. , 1992, Molecular pharmacology.
[37] M. Caron,et al. Constitutive activation of the alpha 1B-adrenergic receptor by all amino acid substitutions at a single site. Evidence for a region which constrains receptor activation. , 1992, The Journal of biological chemistry.
[38] R Henderson,et al. The structure of bacteriorhodopsin and its relevance to the visual opsins and other seven-helix G-protein coupled receptors. , 1990, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.
[39] C. D. Livingstone,et al. Molecular modelling of D2-like dopamine receptors. , 1992, The Biochemical journal.
[40] Jones Ta,et al. Diffraction methods for biological macromolecules. Interactive computer graphics: FRODO. , 1985, Methods in enzymology.
[41] J. Wess. Molecular basis of muscarinic receptor function , 1993 .
[42] J. Baldwin. The probable arrangement of the helices in G protein‐coupled receptors. , 1993, The EMBO journal.
[43] K. Neve,et al. Pivotal role for aspartate-80 in the regulation of dopamine D2 receptor affinity for drugs and inhibition of adenylyl cyclase. , 1991, Molecular pharmacology.
[44] P. Seeman,et al. The conformation of dopamine at its receptor: binding of monohydroxy-2-aminotetralin enantiomers and positional isomers. , 1979, Molecular Pharmacology.
[45] Gebhard F. X. Schertler,et al. Projection structure of rhodopsin , 1993, Nature.
[46] M. Caron,et al. Role of extracellular disulfide-bonded cysteines in the ligand binding function of the beta 2-adrenergic receptor. , 1990, Biochemistry.
[47] B. Kobilka,et al. Amino acid substitutions at position 312 in the seventh hydrophobic segment of the beta 2-adrenergic receptor modify ligand-binding specificity. , 1993, Molecular pharmacology.
[48] R. Henderson. The structure of bacteriorhodopsin and its relevance to other membrane proteins. , 1979, Society of General Physiologists series.
[49] D. Grandy,et al. Cloning and expression of a rat D2 dopamine receptor cDNA , 1988, Nature.
[50] H. Khorana,et al. Cysteine residues 110 and 187 are essential for the formation of correct structure in bovine rhodopsin. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[51] C. Fraser,et al. Site-directed mutagenesis of alpha 2A-adrenergic receptors: identification of amino acids involved in ligand binding and receptor activation by agonists. , 1991, Molecular pharmacology.
[52] P. Seeman,et al. Link between D1 and D2 dopamine receptors is reduced in schizophrenia and Huntington diseased brain. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[53] E. Hulme,et al. Muscarinic acetylcholine receptors. Peptide sequencing identifies residues involved in antagonist binding and disulfide bond formation. , 1990, The Journal of biological chemistry.
[54] B. O'dowd,et al. A single amino-acid difference confers major pharmacological variation between human and rodent 5-HT1B receptors , 1992, Nature.
[55] P. Seeman,et al. Regulation of Anterior Pituitary D2 Dopamine Receptors by Magnesium and Sodium Ions , 1985, Journal of neurochemistry.
[56] J. Shine,et al. Protein-coupled Receptors , 1996 .
[57] R. Baldessarini,et al. A stereochemical and conformational model of dopaminergic agonist and antagonist activity: further evaluation. , 1987, Journal of pharmaceutical sciences.
[58] L. Birnbaumer,et al. G proteins in signal transduction. , 1990, Annual review of pharmacology and toxicology.
[59] R. Henderson,et al. Model for the structure of bacteriorhodopsin based on high-resolution electron cryo-microscopy. , 1990, Journal of molecular biology.
[60] M. Froimowitz,et al. Conformational properties of semirigid antipsychotic drugs: the pharmacophore for dopamine D-2 antagonist activity. , 1991, Journal of medicinal chemistry.
[61] P. Stolk. [Antipsychotic agents]. , 1988, Nederlands tijdschrift voor geneeskunde.
[62] A. Kerlavage,et al. Molecular biology of adrenergic and muscarinic cholinergic receptors. A perspective. , 1989, Biochemical pharmacology.
[63] J. Ponder,et al. Tertiary templates for proteins. Use of packing criteria in the enumeration of allowed sequences for different structural classes. , 1987, Journal of molecular biology.
[64] P. Strange. New insights into dopamine receptors in the central nervous system , 1993, Neurochemistry International.
[65] I. Sylte,et al. Molecular dynamics of dopamine at the D2 receptor. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[66] P. Seeman,et al. The Dopamine/Neuroleptic Receptor , 1984, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.
[67] S. Hjorth,et al. Resolved monophenolic 2-aminotetralins and 1,2,3,4,4a,5,6,10b-octahydrobenzo[f]quinolines: structural and stereochemical considerations for centrally acting pre- and postsynaptic dopamine-receptor agonists. , 1985, Journal of Medicinal Chemistry.
[68] W. C. Probst,et al. Sequence alignment of the G-protein coupled receptor superfamily. , 1992, DNA and cell biology.
[69] S. Roe,et al. Atomic resolution (0.83 A) crystal structure of the hydrophobic protein crambin at 130 K. , 1993, Journal of molecular biology.
[70] H. Kao,et al. Site‐directed mutagenesis of a single residue changes the binding properties of the serotonin 5‐HT2 receptor from a human to a rat pharmacology , 1992, FEBS letters.
[71] P B Sigler,et al. The 2.2 A crystal structure of transducin-alpha complexed with GTP gamma S. , 1994, Nature.
[72] K Konvicka,et al. A reciprocal mutation supports helix 2 and helix 7 proximity in the gonadotropin-releasing hormone receptor. , 1994, Molecular pharmacology.
[73] B. Largent,et al. N-substituted 1,2,3,4,4a,5,6,10b-octahydrobenzo[f]quinolines and 3-phenylpiperidines: effects on central dopamine and sigma receptors. , 1987, Journal of medicinal chemistry.
[74] P. Chanda,et al. Identification of residues important for ligand binding to the human 5-hydroxytryptamine1A serotonin receptor. , 1993, Molecular pharmacology.
[75] H. Akil,et al. Site-directed mutagenesis of the human dopamine D2 receptor. , 1992, European journal of pharmacology.
[76] B. Sommer,et al. The dopamine D2 receptor: two molecular forms generated by alternative splicing. , 1989, The EMBO journal.
[77] C. Strader,et al. Conserved aspartic acid residues 79 and 113 of the beta-adrenergic receptor have different roles in receptor function. , 1988, The Journal of biological chemistry.
[78] C. Fraser. Site-directed mutagenesis of beta-adrenergic receptors. Identification of conserved cysteine residues that independently affect ligand binding and receptor activation. , 1989, The Journal of biological chemistry.
[79] C. Strader,et al. Identification of two serine residues involved in agonist activation of the beta-adrenergic receptor. , 1989, The Journal of biological chemistry.
[80] P. Seeman,et al. Cloning of two additional catecholamine receptors from rat brain , 1990, FEBS letters.